ロード中...
JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性：A2202随访一年结果
OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. METHODS: This study enrolled 63 Chinese patients (32 males and 31 females) in total, whose median age was 55 (25–79) years. The initial dose of ruxolitinib was 30mg/d (25 patients) with a baseline of PLT...
保存先:
| 出版年: | Zhonghua Xue Ye Xue Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Editorial office of Chinese Journal of Hematology
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7364878/ https://ncbi.nlm.nih.gov/pubmed/27801315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|